help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on September 25, 2003, doi:10.1165/rcmb.2003-0304RC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-0304RCv1
30/1/1    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Culver, D. A.
Right arrow Articles by Thomassen, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Culver, D. A.
Right arrow Articles by Thomassen, M. J.
American Journal of Respiratory Cell and Molecular Biology. Vol. 30, pp. 1-5, 2004
© 2004 American Thoracic Society
DOI: 10.1165/rcmb.2003-0304RC

Rapid Communication

Peroxisome Proliferator–Activated Receptor {gamma} Activity Is Deficient in Alveolar Macrophages in Pulmonary Sarcoidosis

Daniel A. Culver, Barbara P. Barna, Baisakhi Raychaudhuri, Tracey L. Bonfield, Susamma Abraham, Anagha Malur, Carol F. Farver, Mani S. Kavuru and Mary Jane Thomassen

Departments of Pulmonary and Critical Care Medicine, Anatomic Pathology, and Cell Biology, Cleveland Clinic Foundation, Cleveland, Ohio

Address correspondence to: Mary Jane Thomassen, Ph.D., Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue/A90, Cleveland, OH 44195. E-mail: thomasm{at}ccf.org

The ligand-activated transcription factor, peroxisome proliferator–activated receptor {gamma} (PPAR{gamma}), has pleiotropic effects on lipid and glucose metabolism as well as modulating immune activity. In Th1-predominant models of inflammatory bowel disease and arthritis, PPAR{gamma} ligands can ameliorate clinical disease severity, partly by downregulating a range of inflammatory cytokines. However, PPAR{gamma} has not been evaluated in chronic sarcoidosis, a disease characterized by persistent activation of Th1 immune responses in alveolar macrophages. We hypothesized that a deficiency of PPAR{gamma} activity contributes to ongoing inflammation in pulmonary sarcoidosis via failure to repress proinflammatory transcription factors. To address this, we studied eight patients with active sarcoidosis and nine healthy control subjects by bronchoscopy. Bronchoalveolar lavage specimens from patients revealed a striking reduction of PPAR{gamma} activity by electrophoretic mobility shift assay in alveolar macrophages compared with healthy control subjects, with a concomitant upregulation of nuclear factor (NF)-{kappa}B activity. Immunostaining and real-time polymerase chain reaction demonstrated reductions of PPAR{gamma} nuclear protein and gene expression. The data show for the first time that alveolar macrophages from patients with active sarcoidosis exhibit activation of NF-{kappa}B and deficiency of PPAR{gamma}. Although these results do not demonstrate a direct causal effect, they are consistent with the hypothesis that insufficient PPAR{gamma} activity contributes to ongoing dysregulated inflammation in pulmonary sarcoidosis by failing to suppress NF-{kappa}B.

Abbreviations: bronchoalveolar lavage, BAL • electrophorectic mobility shift assay, EMSA • interferon, IFN • nuclear factor-{kappa}B, NF-{kappa}B • peroxisome proliferator–activated receptor {gamma}, PPAR{gamma} • peroxisome proliferator response element, PPRE • whole cell extract, WCE




This article has been cited by other articles:


Home page
 J. Immunol.Home page
T. L. Bonfield, M. J. Thomassen, C. F. Farver, S. Abraham, M. T. Koloze, X. Zhang, D. M. Mosser, and D. A. Culver
Peroxisome Proliferator-Activated Receptor-{gamma} Regulates the Expression of Alveolar Macrophage Macrophage Colony-Stimulating Factor
J. Immunol., July 1, 2008; 181(1): 235 - 242.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
N.-B. Nguyen, K. D. Callaghan, A. J. Ghio, D. J. Haile, and F. Yang
Hepcidin expression and iron transport in alveolar macrophages
Am J Physiol Lung Cell Mol Physiol, September 1, 2006; 291(3): L417 - L425.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Bhagavathula, K. C. Nerusu, M. Reddy, C. N. Ellis, A. Chittiboyina, M. Avery, H. A. Pershadsingh, T. W. Kurtz, and J. Varani
BP-1107 [{2-[4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-phenoxy]-ethyl}-methyl-amide]: A Novel Synthetic Thiazolidinedione That Inhibits Epidermal Hyperplasia in Psoriatic Skin-Severe-Combined Immunodeficient Mouse Transplants after Topical Application
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 996 - 1004.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
W. Matsuyama, H. Mitsuyama, M. Watanabe, Y. Shirahama, I. Higashimoto, M. Osame, and K. Arimura
Involvement of Discoidin Domain Receptor 1 in the Deterioration of Pulmonary Sarcoidosis
Am. J. Respir. Cell Mol. Biol., December 1, 2005; 33(6): 565 - 573.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. T. Sadikot, T. S. Blackwell, J. W. Christman, and A. S. Prince
Pathogen-Host Interactions in Pseudomonas aeruginosa Pneumonia
Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1209 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. M. Wu, M. Jin, and C. B. Marsh
Toward functional proteomics of alveolar macrophages
Am J Physiol Lung Cell Mol Physiol, April 1, 2005; 288(4): L585 - L595.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2004 American Thoracic Society.